BETA

2 Amendments of Elżbieta Katarzyna ŁUKACIJEWSKA related to 2008/0261(COD)

Amendment 76 #
Proposal for a directive – amending act
Recital 7
(7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated.
2010/03/12
Committee: ENVI
Amendment 79 #
Proposal for a directive – amending act
Recital 7 a (new)
(7a) No later than five years from the date of entry into force of the enforcement provisions relating to safety features, the Commission should submit to the European Parliament and the Council an assessment report on the application of the safety features referred to in point (o) of Article 54 of Directive 2001/83/EC and their estimated contribution to the reduction of the number of falsified medicines in the legal supply chain in Europe. The report should include an assessment of the safety features of other categories of medicines, including medicinal products not subject to medical prescription as defined in Title VI of Directive 2001/83/EC.
2010/03/12
Committee: ENVI